GlassScriptPhysician profile
Caitlyn A Dillon
NPI 1467041186
$7,188.76
in general payments reported to CMS, 2019-2025
27 companies · $3,147 in 2025
The $3,147 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4.72 · 2023: $159 · 2024: $3,878 · 2025: $3,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,734 · Education: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,734.12 |
| Education | $449.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,140.21 | 2024-2025 | |
| Janssen Biotech, INC. | $937.03 | 2024-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $701.06 | 2023-2025 | Odomzo, Blu-U |
| Regeneron Healthcare Solutions, INC. | $576.95 | 2024-2025 | Dupixent |
| Genzyme Corporation | $559.98 | 2024-2025 | |
| Leo Pharma INC. | $486.97 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $472.65 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $348.18 | 2024-2025 | |
| Incyte Corporation | $331.67 | 2024-2025 | Opzelura, Opzelura |
| Ucb, INC. | $301.85 | 2023-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $271.10 | 2024-2025 | Nemluvio, Aklief |
| Revance Therapeutics, INC. | $229.66 | 2024-2025 | Daxxify |
| Amgen INC. | $129.23 | 2024-2025 | Otezla, Otezla |
| Verrica Pharmaceuticals INC. | $110.98 | 2024 | Ycanth |
| Botanix Sb INC | $100.19 | 2025 | Sofdra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $96.88 | 2024-2025 | Puraply Wound Matrix, Novachor, Puraply Am |
| Tactile Systems Technology INC | $84.54 | 2024 | Entre Plus, Flexitouch Plus |
| Sanofi-Aventis U.S. LLC | $72.00 | 2024 | |
| Pfizer INC. | $60.34 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $39.25 | 2024 | |
| Paratek Pharmaceuticals, INC. | $36.31 | 2024-2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $25.55 | 2024 | Sotyktu |
| Biofrontera INC. | $20.83 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.84 | 2025 | Cabtreo, Jublia |
| Arcutis Biotherapeutics, INC. | $18.66 | 2024 | Zoryve |
| Organon LLC | $12.13 | 2025 | Vtama |
| Genentech USA, INC. | $4.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlyn Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.